Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04207086 |
| Title | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) |
| Acronym | Neo PeLe |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Melanoma Institute Australia |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Melanoma Institute Australia | North Sydney | New South Wales | 2060 | Australia | Details |